[1] [1] LEITER A, VELUSWAMY R R, WISNIVESKY J P. The global burden of lung cancer: current status and future trends[J]. Nat Rev Clin Oncol,2023, 20(9): 624-639. DOI:10.1038/s41571-023-00798-3.

[2] [2] NOORELDEEN R, BACH H. Current and future development in lung cancer diagnosis[J/OL]. Int J Mol Sci, 2021, 22(16): 8661[2024-09-24]. https://pubmed.ncbi.nlm.nih.gov/34445366/. DOI:10.3390/ijms22168661.

[3] [3] DUMA N, SANTANA-DAVILA R, MOLINA J R. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640. DOI:10.1016/j.mayocp.2019.01.013.

[4] [4] THOMPSON E M, STOKER A W. A review of DUSP26: structure, regulation and relevance in human disease[J/OL]. Int J Mol Sci,2021, 22(2): 776[2024-09-24]. https://pubmed.ncbi.nlm.nih.gov/33466673/. DOI:10.3390/ijms22020776.

[5] [5] YU W, IMOTO I, INOUE J,et al. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity[J]. Oncogene, 2007, 26(8): 1178-1187. DOI:10.1038/sj.onc.1209899.

[6] [6] HUANG R H, ZENG Q M, JIANG B,et al. Overexpression of DUSP26 gene suppressed the proliferation, migration, and invasion of human prostate cancer cells[J/OL]. Exp Cell Res, 2024, 442(2):114231[2024-09-24]. https://pubmed.ncbi.nlm.nih.gov/39222869/ DOI:10.1016/j.yexcr.2024.114231.

[7] [7] GRANT M J, HERBST R S, GOLDBERG S B. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC[J]. Nat Rev Clin Oncol, 2021, 18(10): 625-644. DOI:10.1038/s41571-021-00520-1..

[8] [8] LI Y W, WU X, YANG P,et al. Machine learning for lung cancer diagnosis, treatment, and prognosis[J]. Genomics Proteomics Bioinformatics, 2022, 20(5): 850-866. DOI:10.1016/j.gpb.2022.11.003.

[9] [9] DAYLAN A E C, MIAO E, TANG K,et al. Lung cancer in never smokers: delving into epidemiology, genomic and immune landscape, prognosis, treatment, and screening[J]. Lung, 2023, 201(6): 521-529. DOI:10.1007/s00408-023-00661-3.

[11] [11] LU T, YANG X D, HUANG Y W,et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades[J]. Cancer Manag Res, 2019, 11: 943-953. DOI:10.2147/CMAR.S187317.

[12] [12] ZHOU F, QIAO M, ZHOU C C. The cutting-edge progress of immune-checkpoint blockade in lung cancer[J]. Cell Mol Immunol,2021, 18(2): 279-293. DOI:10.1038/s41423-020-00577-5.

[13] [13] GALAN-COBO A, SITTHIDEATPHAIBOON P, QU X,et al. LKB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in KRAS-mutant lung adenocarcinoma[J]. Cancer Res, 2019, 79(13):3251-3267. DOI:10.1158/0008-5472.CAN-18-3527.

[14] [14] LEE H M, MUHAMMAD N, LIEU E L,et al. Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer[J]. Nat Metab, 2024, 6(7): 1310-1328. DOI:10.1038/s42255-024-01066-z.

[15] [15] DAVIES M, ROBINSON M, SMITH E,et al. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways[J]. J Cell Biochem, 2005, 95(5): 918-931. DOI:10.1002/jcb.20458.

[16] [16] GULER S, ZIK B, YALCIN A. Upregulation of dual-specificity phosphatase-26 is required for transforming growth factor 1(TGF 1)-induced Epithelial-mesenchymal transition in A549 and PANC1 cells[J]. Mol Biol Rep, 2022, 49(11): 10195-10204. DOI:10.1007/s11033-022-07893-1.

[17] [17] PALLASCH F B, SCHUMACHER U. Angiotensin inhibition, TGF- and EMT in cancer[J/OL]. Cancers, 2020, 12(10): 2785[2024-09-24]. https://pubmed.ncbi.nlm.nih.gov/32998363/. DOI:10.3390/cancers12102785.

[18] [18] GUO W H, LIU H W, YAN Y,et al. Targeting the TGF- signaling pathway: an updated patent review (2021-present)[J]. Expert Opin Ther Pat, 2024, 34(3): 99-126. DOI:10.1080/13543776.2024.2346325.

[19] [19] BOULDING T, WU F, MCCUAIG R,et al. Differential roles for DUSP family members in epithelial-to-mesenchymal transition and cancer stem cell regulation in breast cancer[J/OL]. PLoS One,2016, 11(2): e0148065[2024-09-24]. https://pubmed.ncbi.nlm.nih.gov/26859151/. DOI:10.1371/journal.pone.0148065.

[20] [20] GAO Y, LI H, HAN Q,et al. Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway[J]. J Cancer, 2020, 11(11): 3151-3164. DOI:10.7150/jca.37267.

[21] [21] CHEN J J, ZENG Y C, WU R,et al. Decreased DUSP26 expression promotes malignant behavior in glioblastoma cellsviaderegulation of MAPK and Akt signaling pathway[J/OL]. Front Oncol, 2021, 11:622826[2024-09-24]. https://pubmed.ncbi.nlm.nih.gov/33718185/./ DOI:10.3389/fonc.2021.622826.